Considering PD-1/PD-L1 inhibitors blockade PD-1/PD-L1 pathways by activating an immune response directed against cancer, it exhibit antitumor activity in the form of a cytostatic, rather than a cytotoxic effect [28]. The gene discussed is PDCD1; the disease is cancer.